PHE - Corporate - UKNSC Non-Invasive Prenatal Testing

The overall aim of the work is to apply the same methods used in a previous review, undertaken by Warwick University for the UK NSC, to review the evidence relating: 1 the accuracy of a new version of the technology (microarray) which was not available at the time of the previous review. This will inform a decision on whether Fetal Anomaly Screening Programme should include microarray technology in future procurement work 2 test accuracy for the detection T21, T18 and T13 in twins. At the time of the previous review there was insufficient evidence to make a recommendation in this area. This review aims to establish whether there is now sufficient evidence and to add the most recent evidence to that analysed in the previous review. This will include the older versions of the technology and micoarray technology.